| 12128040 |
Selective estrogen receptor degraders |
Jeffrey Daniel Cohen |
2024-10-29 |
$5,148,475,000 |
| 11993608 |
Selective estrogen receptor degraders |
Jolie Anne Bastian, Jeffrey Daniel Cohen, Almudena Rubio, Jennifer Anne McMahon |
2024-05-28 |
$5,773,536,000 |
| 11634426 |
Selective estrogen receptor degraders |
Jolie Anne Bastian, Jeffrey Daniel Cohen, Almudena Rubio, Jennifer Anne McMahon |
2023-04-25 |
$844,176,000 |
| 11117902 |
Selective estrogen receptor degraders |
Jolie Anne Bastian, Jeffrey Daniel Cohen, Almudena Rubio, Jennifer Anne McMahon |
2021-09-14 |
$897,128,000 |
| 10759786 |
1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer |
Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen +3 more |
2020-09-01 |
$556,181,000 |
| 10654866 |
Selective estrogen receptor degraders |
Jolie Anne Bastian, Jeffrey Daniel Cohen, Almudena Rubio |
2020-05-19 |
$925,988,000 |
| 10344018 |
Pyrazolylaminobenzimidazole derivatives as JAK inhibitors |
Jolie Anne Bastian, Joshua Clayton |
2019-07-09 |
$532,671,000 |
| 10323019 |
Pyrazolylaminobenzimidazole derivatives as JAK inhibitors |
Jolie Anne Bastian, Joshua Clayton, David Coates, Timothy Andrew Woods |
2019-06-18 |
$560,196,000 |
| 9872853 |
2,3-dihydro-1H-indole compounds |
Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen +3 more |
2018-01-23 |
$162,614,000 |
| 8507490 |
Tetrasubstituted pyridazine hedgehog pathway antagonists |
Jolie Anne Bastian, Julia Marie Clay, Jeffrey Daniel Cohen, Philip Arthur Hipskind, Karen L. Lobb +2 more |
2013-08-13 |
$128,561,000 |
| 8445493 |
Tetrasubstituted pyridazines hedgehog pathway antagonists |
Jolie Anne Bastian, Julia Marie Clay, Takako Wilson (nee Takakuwa), Michelle Lee Thompson, Philip Arthur Hipskind |
2013-05-21 |
$130,150,000 |
| 8404687 |
Disubstituted phthalazine hedgehog pathway antagonists |
Jolie Anne Bastian, Philip Arthur Hipskind, Takako Wilson (nee Takakuwa) |
2013-03-26 |
$253,353,000 |
| 7297706 |
Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disorders |
Michael Robert Wiley, Christopher William Murray, Stephen Young, Jolie Anne Bastian |
2007-11-20 |
$175,995,000 |
| 7294627 |
Chemical compounds |
Steven Douglas Hiscock, Stuart Donald Jones, Stephen Young, Michael Robert Wiley |
2007-11-13 |
$94,713,000 |
| 7265121 |
Chemical compounds |
Michael Robert Wiley, John Walter Liebeschuetz |
2007-09-04 |
$45,006,000 |
| 7265127 |
β3 adrenergic agonists |
Jolie Anne Bastian, Gerd Ruehter, Theo Schotten |
2007-09-04 |
$45,006,000 |
| 7253181 |
β3 adrenergic agonists |
Jolie Anne Bastian, Gerd Ruehter, Theo Schotten |
2007-08-07 |
$201,033,000 |
| 7241772 |
β3 adrenergic agonists |
Jolie Anne Bastian, Gerd Ruehter, Theo Schotten |
2007-07-10 |
$166,479,000 |
| 7208505 |
β3 adrenergic agonists |
Jolie Anne Bastian, Rushad E. Karanjawala, Cynthia Darshini Jesudason, Theo Schotten, Britta Evers +9 more |
2007-04-24 |
$185,204,000 |
| 7205407 |
3-Substituted oxindole β3 agonists |
Jolie Anne Bastian, Gerd Ruehter, Theo Schotten |
2007-04-17 |
$53,357,000 |
| 7160909 |
Cyclopenta[b]indole derivatives as sPLA2 inhibitors |
Michael Dean Kinnick, Edward David Mihelich, John Michael Morin, Jr., Jason Scott Sawyer |
2007-01-09 |
$58,894,000 |
| 7122680 |
3-Substituted oxindole β3 agonsists |
Cynthia Darshini Jesudason, Freddie Craig Stevens, John A. Werner |
2006-10-17 |
$107,980,000 |
| 7115609 |
Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases |
Stuart Donald Jones, Michael Robert Wiley |
2006-10-03 |
$111,542,000 |
| 7109231 |
Cyclohept[b]indole derivatives |
Michael Dean Kinnick, Edward David Mihelich, John Michael Morin, Jr., Jason Scott Sawyer |
2006-09-19 |
$116,370,000 |
| 7087635 |
3-substituted oxindole β3 agonists |
Jolie Anne Bastian, Cynthia Darshini Jesudason, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco +7 more |
2006-08-08 |
$73,993,000 |
